European Heart Journal - Cardiovascular Pharmacotherapy · 11 Nov 2026
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial
Frida Rykind-Eriksenh-index 0, Anna Meta Dyrvig Kristensen, Therese Holmager, Harun Caglar, Johanne E Nyen, Ann-Dorthe Zwisler, Jess Lambrechtsen, Svend E Jensen, John Munkhaugen, Eva Prescotth-index 76
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background and Aims Contemporary evidence on the effects of beta-blockers on health-related quality of life (HRQoL) after myocardial infarction (MI) in patients without heart failure is limited, despite widespread use. In this prespecified substudy of the DANBLOCK trial, we aimed to assess whether beta-blocker therapy influences HRQoL after MI in patients with left ventricular ejection fraction (LVEF) >40%. Methods Patients with a recent (≤14 days) MI and LVEF >40% were randomised to open-label beta-blocker therapy or no beta-blocker. HRQoL was assessed at baseline and at three-, 12-, and 24-months using the EQ-5D-5L questionnaire and the EQ visual analogue scale (EQ VAS). The primary endpoints were between-group differences in change from baseline to each follow-up visit estimated by a linear mixed-effects model. Results Among 2707 randomised patients, 2681 (99%) completed at least one EQ-5D-5L questionnaire. Median EQ-5D and EQ VAS scores at baseline were 0.95 (Interquartile range [IQR]: 0.87-1.00) and 77 (IQR: 65-87), respectively. Scores remained stable throughout follow-up. No significant between-group differences for EQ-5D index score and EQ VAS score were observed at any time point. At 12 months, mean difference (beta-blocker minus no beta-blocker) in EQ-5D index- and EQ VAS score was -0.001 (95% confidence interval [CI], -0.016 to 0.013, P=0.86) and -1.35 (95% CI, -2.85 to 0.15, P=0.08), respectively. Results were consistent in prespecified subgroups (age, sex, type of MI, and LVEF). Conclusion Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Eva Prescott has the highest h-index among the authors (76).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.